Cybersecurity researchers have discovered a JScript-based command-and-control (C2) framework called PeckBirdy that has been put to use by China-aligned APT actors since 2023 to target multiple ...

So, you’re building a web app and trying to figure out if React or Vue.js is the way to go in 2026. It’s a big decision, and honestly, it can feel a bit overwhelming with all the options out there.

Ability to upgrade graphics on a laptop is a PC nerd’s dream. Comes with six hot-swappable expansion slots for ports. Bright, color-accurate screen with 165-Hz refresh rate. Decent gaming performance ...

For the third year in a row, Fierce Biotech’s Layoff Tracker is topping the tree as the story with the highest number of reads. The relentless nature of industry layoffs has garnered the most ...

Could 2026 be the year of the beautiful back end? We explore the range of options for server-side JavaScript development, from Express to Next and all the rest. A grumpy Scrooge of a developer might ...

Facepalm: A widely used web technology is affected by a serious security vulnerability that can be exploited with minimal effort to compromise servers. Known as "React2Shell," the flaw may require ...

A new JavaScript framework is making waves in the developer community, promising faster performance, simpler syntax, and features React doesn’t offer. Learn why some coders are considering a switch.

Framework delivers on its promise to build a truly upgradeable gaming laptop. But keeping that new GPU cool comes at a cost. Framework’s late-2025 upgrade for the laptop is arguably more important ...

A new evidence-based framework aims to establish a U.S. industry standard for measuring health equity efforts. Put out by the Institute for Healthcare Improvement (IHI), the white paper has been in ...

For years, JavaScript has reigned as the undisputed language of the web, powering everything from single-page apps to massive enterprise systems through frameworks like React, Angular, and Vue. But ...

AstraZeneca and Daiichi Sankyo are teeing up a TROP2 showdown with Gilead Sciences in first-line triple-negative breast cancer. China's InnoCare Pharma agreed to out-license three autoimmune ...

Sealed court documents obtained by Fierce Biotech reveal how Novo Nordisk and Singapore's KBP Biosciences went from partners in a $1.3 billion deal to legal foes. Takeda has decided to cease all ...